About 86 million American adults have total cholesterol levels above 200 mg/dL. Most of them have been told to “watch their cholesterol” — a directive so vague it’s almost useless. Watch it do what, exactly? Go up? Go down? The reality is that a standard lipid panel gives you four or five numbers, and most patients leave their doctor’s office understanding maybe one of them, if that.
Cholesterol itself isn’t the villain it’s been painted as for 50 years. Your body manufactures roughly 80% of the cholesterol in your blood; dietary cholesterol plays a surprisingly modest role for most people. Cholesterol is essential — it’s a building block for cell membranes, a precursor to vitamin D and steroid hormones, and necessary for bile acid production. The problem isn’t cholesterol existing in your blood. The problem is specific types, in specific amounts, in specific contexts.
Key Takeaways
- Total cholesterol is nearly useless as a standalone number — the ratio and subtypes matter far more
- LDL cholesterol drives atherosclerosis; the current evidence supports “lower is better” with no known floor for benefit
- HDL cholesterol is associated with lower risk, but artificially raising it with drugs hasn’t improved outcomes
- Triglycerides above 150 mg/dL, particularly when combined with low HDL, signal metabolic dysfunction
- Apolipoprotein B (ApoB) and LDL particle number may be better risk predictors than standard LDL-C, and more doctors are starting to test them
What Your Lipid Panel Actually Measures
When you get a standard lipid panel, the lab reports four primary numbers. Here’s what each one means — and doesn’t mean.
Total Cholesterol
This is the sum of all cholesterol in your blood: LDL + HDL + 20% of your triglycerides (approximately). Current guidelines consider below 200 mg/dL “desirable.” Frankly, this number alone tells you very little. Someone with a total cholesterol of 220 driven by high HDL is in a completely different risk category than someone at 220 driven by high LDL. Yet both get the same “your cholesterol is high” warning.
Total cholesterol was the primary metric used in early cardiovascular research because it was easy to measure. It’s a relic. It’s still reported because patients expect it and guidelines reference it, but cardiologists making treatment decisions rarely care about it in isolation.
LDL Cholesterol (Low-Density Lipoprotein)
LDL is the primary driver of atherosclerosis — the buildup of plaque in arterial walls that leads to heart attacks and strokes. LDL particles infiltrate the endothelium (the inner lining of arteries), become oxidized, and trigger an inflammatory response that progressively narrows blood vessels. This isn’t theoretical. Mendelian randomization studies — which use genetic variants as natural experiments — have demonstrated a clear, causal relationship between lifetime LDL exposure and cardiovascular events.
Standard optimal range: below 100 mg/dL. For people with existing heart disease or high risk: below 70 mg/dL. Some aggressive guidelines push for below 55 mg/dL in very high-risk patients.
Here’s the catch: the LDL-C value on your standard lipid panel is almost always calculated, not directly measured, using the Friedewald equation. This calculation becomes inaccurate when triglycerides are above 400 mg/dL or in certain other conditions. If precision matters — and for treatment decisions, it often does — direct LDL measurement or advanced lipid testing is better.
HDL Cholesterol (High-Density Lipoprotein)
HDL particles help transport cholesterol away from artery walls back to the liver for disposal — a process called reverse cholesterol transport. Higher HDL has consistently been associated with lower cardiovascular risk in epidemiological studies. Current targets: above 40 mg/dL for men, above 50 mg/dL for women.
But the HDL story has a major twist. Multiple drug trials that pharmacologically raised HDL (torcetrapib, dalcetrapib, niacin in the AIM-HIGH trial) failed to reduce heart attacks and strokes. Some actually increased harm. This suggests that HDL cholesterol levels are a marker of cardiovascular health rather than a direct cause of protection. Your HDL level tells you something about your metabolic state, but forcing the number up artificially doesn’t fix the underlying problem.
What raises HDL naturally? Regular aerobic exercise (the most reliable), moderate alcohol intake (though the overall health tradeoffs make this a bad strategy), weight loss, and smoking cessation.
Triglycerides
Triglycerides are fat molecules circulating in your blood, primarily packaged in VLDL (very low-density lipoprotein) particles. They rise after meals and are strongly influenced by carbohydrate intake, alcohol, and metabolic health.
Optimal: below 150 mg/dL. Borderline high: 150-199 mg/dL. High: 200-499 mg/dL. Very high: 500 mg/dL and above.
Elevated triglycerides — especially when paired with low HDL — are a hallmark of insulin resistance and metabolic syndrome. This pattern is far more common than isolated high LDL, and it’s often missed because doctors focus on LDL. If your triglycerides are elevated, it’s worth investigating your blood sugar and insulin levels. There’s substantial overlap between the metabolic pathways driving high triglycerides and those driving type 2 diabetes risk.
Very high triglycerides (above 500 mg/dL) carry an additional, separate risk: acute pancreatitis. This is a medical emergency and requires aggressive treatment.
Beyond Standard Testing: ApoB and Particle Number
The standard lipid panel has a fundamental limitation. It measures the amount of cholesterol carried in lipoprotein particles, not the number of particles themselves. Why does this matter?
Think of LDL particles as cars on a highway and cholesterol as passengers. Two people can have the same total number of passengers (same LDL-C) but very different numbers of cars. One person has a few large, passenger-packed cars. The other has many small cars with fewer passengers each. The person with more cars — more LDL particles — has higher cardiovascular risk, because each particle that enters the arterial wall can trigger plaque formation regardless of how much cholesterol it carries.
Apolipoprotein B (ApoB) is a protein found on the surface of every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a). Measuring ApoB gives you a direct count of all potentially harmful particles. A growing body of evidence, including a 2021 consensus statement from the European Atherosclerosis Society, suggests ApoB is a better predictor of cardiovascular risk than LDL-C alone.
LDL particle number (LDL-P) specifically counts LDL particles using NMR spectroscopy. It’s conceptually similar to ApoB but isolates LDL specifically.
These tests are most valuable when there’s a discordance between standard LDL-C and actual risk — common in people with metabolic syndrome, diabetes, or insulin resistance, who often have “normal” LDL-C but elevated particle numbers. If your triglycerides are high and HDL is low but your LDL-C looks fine, advanced testing may reveal hidden risk.
Not every patient needs these tests. But if you’re debating whether to start a statin, or if standard numbers seem inconsistent with your risk profile, asking for an ApoB level is reasonable and increasingly supported by guidelines.
What Actually Causes High Cholesterol?
Genetics
Familial hypercholesterolemia (FH) affects roughly 1 in 250 people — far more common than most doctors realize. Heterozygous FH typically produces LDL-C levels of 190-400 mg/dL from birth, independent of diet or lifestyle. Homozygous FH (much rarer, about 1 in 250,000) can produce LDL-C above 500 mg/dL and causes heart attacks in childhood if untreated.
If your LDL is persistently above 190 mg/dL, or if you have a family history of early heart disease (heart attack before 55 in men, before 65 in women), FH should be on the radar. It’s diagnosed through a combination of clinical criteria and genetic testing. Treatment is almost always medication-based — lifestyle changes alone can’t overcome the genetic defect in LDL receptor function.
Beyond FH, polygenic influences on cholesterol are substantial. Hundreds of gene variants each make small contributions to your baseline cholesterol levels. This is why two people eating identical diets can have wildly different lipid panels.
Diet and Lifestyle
Dietary saturated fat raises LDL cholesterol in most people. This has been demonstrated repeatedly in controlled feeding studies and is not seriously debated in mainstream nutrition science, despite what certain popular books claim. Replacing saturated fat with unsaturated fat lowers LDL.
Dietary cholesterol (eggs, shrimp, organ meats) has a more modest effect. For most people, dietary cholesterol has a relatively small impact on blood cholesterol. The 2020 Dietary Guidelines Advisory Committee acknowledged this but still recommended keeping dietary cholesterol intake reasonable, partly because high-cholesterol foods often come packaged with saturated fat.
Trans fats — found in partially hydrogenated oils — are the worst offenders. They raise LDL and lower HDL simultaneously. Most countries have banned or restricted them, but they still lurk in some processed foods.
Excess body weight, particularly visceral fat, drives up triglycerides and can increase LDL particle number even when LDL-C appears normal. Physical inactivity independently worsens lipid profiles.
Medical Conditions
Hypothyroidism is a surprisingly common and underrecognized cause of elevated cholesterol. An underactive thyroid slows LDL receptor activity, causing LDL to accumulate. If your cholesterol suddenly worsened with no obvious lifestyle change, getting your thyroid checked is a reasonable step. Other conditions that can raise cholesterol include kidney disease, liver disease, and certain medications (thiazide diuretics, some beta-blockers, corticosteroids).
Statins: The Controversy That Shouldn’t Be Controversial
Statins reduce LDL cholesterol by 30-50% depending on the type and dose. They also reduce cardiovascular events — heart attacks, strokes, cardiovascular death — by roughly 25-35% in high-risk populations. This is supported by meta-analyses including hundreds of thousands of patients across dozens of randomized controlled trials. The Cholesterol Treatment Trialists’ (CTT) Collaboration data is about as solid as evidence gets in medicine.
So why the controversy? Partly because statins have real side effects. Muscle pain (myalgia) occurs in about 5-10% of patients in clinical practice — higher than reported in trials, possibly due to nocebo effects (expecting side effects causes them). Statins slightly increase the risk of developing type 2 diabetes, particularly at higher doses and in people already predisposed. Liver enzyme elevations occur but are rarely clinically significant.
Then there’s the discourse driven by statin skeptics — a mix of legitimate questions about overtreatment in low-risk populations and frankly irresponsible fear-mongering that has caused high-risk patients to stop medications they genuinely need. If you have existing cardiovascular disease, the evidence for statins is overwhelming. If you’re a low-risk person whose doctor suggested a statin based solely on a mildly elevated total cholesterol, questioning that recommendation is reasonable.
The decision to start a statin should be based on overall cardiovascular risk — factoring in age, blood pressure, smoking status, diabetes, and family history — not just a single cholesterol number. The ACC/AHA pooled cohort equations or the MESA risk calculator can help quantify your 10-year risk. Generally, a 10-year risk above 7.5-10% is where the conversation about statins begins.
Non-Statin Medications
Ezetimibe blocks cholesterol absorption in the gut and reduces LDL by about 15-20%. Often added to a statin for additional lowering.
PCSK9 inhibitors (evolocumab, alirocumab) are injectable medications that dramatically lower LDL — by 50-60% on top of statin therapy. They’re typically reserved for patients with FH or those who can’t reach target LDL on statins. The FOURIER trial showed evolocumab reduced cardiovascular events by 15% over 2.2 years. The main barrier is cost, though prices have come down significantly.
Bempedoic acid works upstream in the same cholesterol synthesis pathway as statins but doesn’t accumulate in muscle tissue, making it an option for patients with statin-related muscle symptoms. The CLEAR Outcomes trial showed a 13% reduction in major cardiovascular events.
Icosapent ethyl (purified EPA omega-3) is specifically indicated for elevated triglycerides in patients already on statins. The REDUCE-IT trial showed a 25% reduction in cardiovascular events, though some debate exists about the contribution of the mineral oil placebo to these results.
When to See a Doctor
Get a lipid panel if:
- You’re over 20 and have never had one (baseline screening is recommended for all adults)
- You have a family history of early heart disease or known familial hypercholesterolemia
- You have diabetes, high blood pressure, or other cardiovascular risk factors
- You’re on cholesterol-lowering medication and due for monitoring
- You’ve made significant lifestyle changes and want to see if they’re working
If your LDL is persistently above 190 mg/dL, push for evaluation for familial hypercholesterolemia — it’s underdiagnosed and undertreated.
Frequently Asked Questions
How often should I get my cholesterol checked?
Adults with normal levels and no risk factors: every 4-6 years. Adults with risk factors, borderline levels, or on treatment: annually, or more frequently if medication adjustments are being made. Children with a family history of FH or early heart disease should be screened between ages 9 and 11.
Do eggs raise cholesterol?
For most people, modestly. A large egg contains about 186 mg of cholesterol, but dietary cholesterol is a weak driver of blood cholesterol compared to saturated fat intake. Most healthy adults can eat 1-3 eggs per day without significantly affecting their lipid profile. If you have familial hypercholesterolemia or existing heart disease, your doctor may advise more caution.
Can exercise alone fix high cholesterol?
Exercise reliably raises HDL (by about 5-10%), can modestly lower triglycerides, and slightly reduces LDL. It also shifts LDL particles toward larger, potentially less atherogenic subtypes. However, for significantly elevated LDL — particularly genetically driven elevations — exercise alone usually isn’t sufficient. Think of exercise as an essential complement to other interventions, not a replacement.
What’s the deal with “good” and “bad” cholesterol?
The “good” (HDL) and “bad” (LDL) framing is an oversimplification but directionally correct. LDL particles are the primary drivers of plaque formation. HDL particles participate in removing cholesterol from arteries. The simplification breaks down when people assume that any strategy to raise HDL or lower LDL is equally beneficial — the mechanism matters, not just the number on the lab report.
Should I take red yeast rice instead of a statin?
Red yeast rice contains monacolin K, which is chemically identical to lovastatin. So you’d be taking a statin — just an unregulated one with variable potency and potential contaminants. If you need a statin, take a pharmaceutical-grade statin with known dosing. If you don’t need a statin, you don’t need red yeast rice either. The “natural” label doesn’t make it safer or more effective.
